✦ LIBER ✦

Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for korean women with breast cancer: Retrospective cohort study of the korean breast cancer society database

✍ Scribed by Jae Jeong Yang; Sue K. Park; Lisa Y. Cho; Wonshik Han; Boyoung Park; Hyeongsu Kim; Kun-Sei Lee; Seo Kyung Hahn; Sung-il Cho; Sei-Hyun Ahn; Dong-Young Noh

Book ID: 113544234
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 153 KB
Volume: 32
Category: Article
ISSN: 0149-2918
DOI: 10.1016/j.clinthera.2010.05.013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

0242 Cost effectiveness analysis of letr

0242 Cost effectiveness analysis of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive breast cancer

✍ T. Hashem; M. Al-Sherbini; N. Abd El-Bary; M. Swiha 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 52 KB

PCN116 A SURVIVAL BASED COST-EFFECTIVENE

PCN116 A SURVIVAL BASED COST-EFFECTIVENESS ANALYSIS OF 5 YEARS LETROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER: CANADIAN PERSPECTIVE

✍ K El Ouagari; S Kaura; JD Karnon 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

P181 Cost-effectiveness analysis of letr

P181 Cost-effectiveness analysis of letrozole vs. tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer: the Belgian perspective

✍ J. Karnon; M. Berli`ere; H. Depypere; L. Dirix; G. Jerusalem; P. Neven; R. Parid 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB

PCN32 COST-EFFECTIVENESS ANALYSIS OF LET

PCN32 COST-EFFECTIVENESS ANALYSIS OF LETROZOLE VERSUS TAMOXIFEN AS INITIAL ADJUVANT THERAPY IN HORMONE-RECEPTOR POSITIVE POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER IN THE UK

✍ J Karnon; TE Delea; NL Papo; V Barghout; SK Thomas; SR Johnston 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

Postoperative adjuvant randomised trial

Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the nishinihon cooperative study group of adjuvant chemoendocrine therapy for breast cancer (ACETBC) of Japan

✍ T. Morimoto; M. Ogawa; K. Orita; K. Sugimachi; T. Toge; K. Dohi; Y. Nomura; Y. M 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 899 KB

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB